🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Energy Sector SEC Filings — April 27, 2026

The 12 filings for the USA S&P 500 Energy stream reveal limited core energy activity, headlined by Kinder Morgan's upcoming Barclays conference on May 5, 2026, amid a broader surge in cross-sector M&A announcements spanning biotech (XOMA/Ligand acquisition at 14% premium, Generation Bio tender) and real estate (Real Brokerage's $880M RE/MAX deal with $30M synergies). COPT Defense Properties stands out with robust Q1 2026 results: net income +10.8% YoY to $40.1M, NOI +7.2% YoY to $115.2M, FFO/share +6.2% to $0.69, and stable 6.1x net debt/EBITDA. Ligand raised 2026 guidance post-XOMA deal to revenue $270-310M (up from $245-285M), royalties $225-250M (up from $200-225M), and adj EPS $8.50-9.50 (up from $8.00-9.00), signaling M&A-driven optimism. Rochester Wealth's 13F shows modest energy exposure with Chevron ($1.66M) and Exxon ($1.05M) amid ETF-heavy portfolio. Positive/mixed sentiments dominate (9/12), with forward catalysts in H2 2026 deal closes; however, SPAC delistings introduce short-term volatility. Portfolio-level trends highlight accretive M&A and stable leverage, contrasting quiet energy ops beyond KMI visibility event.

7 high priority 5 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — April 27, 2026

Across 50 SEC filings from April 27, 2026, a dominant theme is executive leadership transitions in 25+ companies, with 70% involving promotions/internal hires (e.g., Booz Allen, Crane, Matador) signaling management continuity and conviction amid sector growth. M&A activity surges with $16.55B+ in deals including Sun Pharma's $11.75B Organon buyout, BioMarin's $4.8B Amicus acquisition, and SPAC mergers like Miluna/CADV.AI, bolstering portfolios in pharma, tech, and energy. Financial flexibility trends via 12 credit facility amendments/expansions (e.g., Riot's $200M BTC-collateralized line, Bentley's $550M incremental term loans), while capital raises like Auddia's $12M offering and GAMCO's ATM support liquidity. Period-over-period data sparse but highlights PACS Group's 29.3% YoY revenue growth to $5.29B, Fulcrum Therapeutics' Q1 net loss widening 7% YoY to $18.9M (R&D +5%, G&A +16%), and cash runway extensions (Fulcrum to 2029). Positive sentiment in 60% of filings underscores stability, but restatements (Driven Brands) and settlements (Oppenheimer $70M) flag risks; portfolio implication: overweight pharma/energy on M&A catalysts, monitor financials for reporting integrity.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 27, 2026

Across 50 SEC filings from April 27, 2026, primarily involving non-DJ30 names but with Verizon (DJ30) as a standout, overarching themes include peak proxy season with 20+ AGMs scheduled May-June 2026, positive biotech clinical readouts, M&A activity, and 13F snapshots revealing institutional mega-cap tech bias (e.g., AAPL top holding in 12/15 13Fs). Period-over-period trends show telecom resilience (Verizon Q1 revenue +2.9% YoY, EBITDA +6.7% YoY, EPS +7.6% YoY) contrasting credit/fintech pressures (Golub NAV -4.0% QoQ, Qfin net income -4.4% YoY, Hemab losses +31% YoY to $63.9M); operational metrics highlight Verizon's record postpaid adds (+55k Q1) and Easterly's Core FFO $0.77/share. Critical developments: Verizon raised FY2026 Adjusted EPS guidance to $4.95-$4.99 (+5-6% YoY), RE/MAX M&A forming 180k-agent platform, Veradermics Phase 2/3 hair loss trial success (30-33 hairs/cm² vs placebo 7.3, p<0.0001). Portfolio-level patterns indicate bullish biotech/health catalysts (5/7 positive sentiment), mixed credit (NAV compression amid stable leverage), and heavy tech allocations in 13Fs (~20-30% AAPL/AMZN/GOOG across filers) signaling conviction in DJ30 tech giants like AAPL. Capital allocation favors dividends/FCF (Verizon FCF +4% YoY to $3.8B, Solstice $0.075/share div, Easterly $0.45/share), with low buybacks but SPAC IPOs and shelf registrations for fundraising.

19 high priority 31 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 27, 2026

The April 27, 2026, daily digest of 50 SEC filings reveals a peak proxy season with over 20 DEF/DEFA14A filings focused on annual meetings in June 2026, emphasizing governance, equity plan expansions, and auditor ratifications amid neutral sentiment. M&A activity dominates high-materiality events, including Organon's $14/share acquisition by Sun Pharma (103% premium, $11.75B EV) and Cintas' merger with UniFirst (cash + stock, UniFirst owners get 3.4% of combined entity). Q1 earnings show mixed trends: Domino's Pizza revenues +3.5% YoY to $1.15B with ops income +9.6%, but EPS -4.6%; Heartland Express revenues -19.7% YoY to $176.3M with net loss vs prior profit; Ladder Capital NII +13% YoY but net income -78%. Capital allocation remains shareholder-friendly with Domino's $1B buyback + $1.99 dividend, Heartland $0.02 dividend, while risks emerge from Driven Brands' financial restatements and Medtronic's cyber incident. Broader patterns include 13F filings showing institutional overweight in tech giants (Apple, Amazon across multiple managers), zero-revenue persistence in Alternus Clean Energy (-100% YoY), and positive debt reductions (New ERA $50M note prepaid). Portfolio-level: Sporadic revenue growth (avg ~3% where reported) contrasts margin resilience in some (Domino's supply chain +60bps), signaling cautious optimism in consumer/pharma amid transport weakness.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly encompassing retail, auto, and adjacent sectors amid mixed inclusions), Q1 2026 earnings reveal resilient net income growth in financials and select industrials (e.g., Lakeland +32% YoY, Bank of Hawaii +30.6% YoY) with NIM expansions averaging +7bps across reporting banks, offsetting margin pressures elsewhere; revenue trends mixed with outliers like Solaris +55% QoQ but Kforce flat YoY. M&A momentum accelerates with BioMarin $4.8B Amicus close, multiple bank mergers (Flushing/OceanFirst by June 1) securing approvals, and Tesla registering 304M shares for Musk's 2018 award signaling milestone achievement. 13F portfolios (15+ filings) show extreme concentration in mega-tech (AAPL, MSFT, AMZN, NVDA topping most), underscoring conviction amid Consumer Discretionary volatility. Capital allocation favors returns (Kforce $11.7M repos + $6.8M divs; Solaris $0.12 div), but cash burn widens losses in biotech/energy (Fulcrum -$18.9M). Guidance mostly raised/issued (Solaris Q2 EBITDA $83-93M up from prior), building Q2 catalysts; sentiment mixed (18/50), with portfolio-level margin stability but deposit/loan softness in banks.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 27, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (though heavily skewed to financials/banks with limited pure healthcare), key themes include mixed Q1 2026 results with YoY net income surges (Lakeland Financial +32% to $26.5M, Cincinnati Financial swing from -$90M to +$274M, HBT adjusted +12.4% QoQ) offset by QoQ declines and merger costs, accelerating M&A with full regulatory nods for OceanFirst/Flushing (close by June 1) and HBT/CNB completed adding $1.8B assets. Healthcare highlights feature Sagimet Biosciences' strong partner Phase 3 acne data (33.2% success vs 14.6% placebo, US Ph3 2H26), Medtronic's contained cyber incident (no material impact expected), and strong proxy approvals at Pfizer/Cigna (94-98% director support). Capital allocation trends bullish with share repurchases ramping (Waterstone +2M shares auth to 2.1M avail, FB Financial $175M renewed thru 2027, Lakeland $21.2M remaining, Cincinnati $179M Q1) and dividend hikes (Cincinnati +8% to $0.94/share). Forward-looking catalysts cluster in June (mergers, AGMs), while 13F filings reveal broad ETF/stock holdings neutral. Portfolio-level, financials drive consolidation/returns themes, healthcare shows biotech promise amid cyber/governance risks; actionable now: buy merger arb plays, monitor deposit trends.

12 high priority 38 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 27, 2026

Across 50 DEF 14A filings, neutral sentiment dominates (42/50), with positive tones in biotech (e.g., EyePoint, Cognition, Xencor) highlighting clinical progress and cash runways, while mixed sentiment emerges in consumer (Freshpet sales growth slowed to 13% from 27% YoY) and distressed small caps (e.g., reverse splits in MetaVia, SCYNEXIS). Executive compensation shows YoY increases where detailed, such as Zomedica CEO +17.7% to $762K and Krispy Kreme CEO +47% to $3.7M despite no incentives, signaling potential pay-for-performance misalignment amid limited financial period comparisons (only 8/50 provide YoY metrics). Common themes include equity incentive plan expansions (25/50 filings, avg +2-5M shares), director elections, auditor ratifications, and virtual June 2026 AGMs, with biotech-heavy portfolio (22/50) featuring forward-looking catalysts like EyePoint's Phase 3 topline mid-2026. Portfolio-level trends: Revenue growth where reported (ExlService +13.6% YoY) contrasts slowdowns (Freshpet -14pp YoY growth deceleration), no widespread insider trading but M&A activity (SkyWater merger, Keenova spin-off) flags restructuring. Capital allocation leans toward equity dilution over dividends/buybacks, implying funding needs; implications include near-term AGM voting risks and biotech alpha from trials.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 27, 2026

The IPO Pipeline stream shows robust activity with six S-1 filings on April 27, 2026, spanning biopharma, medical devices, EV/AI pivot, semiconductors/optics, and a SPAC, alongside Cintas' S-4 merger filing for UniFirst acquisition. Overarching themes include strategic pivots (e.g., Envirotech to drones/AI), clinical successes (Veradermics' Phase 2/3 hair loss data exceeding endpoints), and dilution risks from warrants/resales across multiple filers. Period-over-period insights are limited in excerpts, but Envirotech raised $3.1M QoQ/Q1 2026 from SEPA (leaving $13.5M available), while others disclose FY2025/Q4 data without quantified YoY trends. Positive sentiments dominate high-materiality events like Veradermics (79-86% PRO response) and Cintas (Croatti family controls 2/3 votes), signaling near-term catalysts. Portfolio-level patterns reveal healthcare/biopharma outperformance via trial data vs. neutral/mixed tech/EV filings hampered by tariffs/debt. Market implications: Surging IPO momentum in underserved niches like oral hair loss therapies ($9B market) and U.S. drones, but watch dilution and concentrations.

7 high priority 7 total filings
· daily

Global High-Priority Regulatory Events — April 27, 2026

Across 50 filings focused on global high-priority market events, proxy statements (DEF 14A) dominate with 15+ neutral governance updates for May-June 2026 AGMs, signaling routine shareholder engagements amid virtual formats. M&A activity shines positively, including Sun Pharma's $11.75B Organon acquisition (early 2027 close) and Cintas-UniFirst merger, bolstering portfolios in pharma and uniforms. Financial trends are mixed: 7/15 quantified reports show revenue declines averaging -18% YoY (e.g., CooTek -28.4%, Nature Wood -10.7%), but outliers like Domino's +3.5% and HUYA +7% buck the trend; net losses widened in 6/10 cases (avg +50% YoY) yet improved in Alternus (-64%). IPO/SPAC filings (10+) indicate capital raising frenzy, while distress signals emerge in insolvency (Vikas WSP), financial restatements (Driven Brands), and settlements (Oppenheimer $70M). Sector patterns highlight pharma/biotech catalysts (Fulcrum trials H2 2026) and energy deals (MRPL JV, US Energy helium Q1 2027), with capital allocation favoring dividends/buybacks (Domino's $75M repurchases +47% YoY). Overall, actionable alpha lies in M&A synergies and biotech readouts versus risks from reporting delays and revenue softness.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 27, 2026

Across 28 filings in the Financial Results & Earnings stream, overarching themes include mixed sentiment with robust revenue growth in industrials (e.g., Steel Dynamics +19% YoY, Celestica +52.8%), insurance (Cincinnati swing to profit), and M&A-driven tech (Sanmina sales doubled), contrasted by sharp declines in microcaps/development (International Land -70% YoY revenue) and retail (Albertsons operating income -53%). Period-over-period trends show 14/28 companies with YoY revenue growth averaging +20% for outperformers, but aggregate profitability mixed due to margin pressures (e.g., Domino's net income -6.6%) and one-time gains; cash flows deteriorated in 12 firms (avg -20% YoY operating cash). Capital allocation emphasizes shareholder returns with buybacks in 10 companies (e.g., Domino's +50% YoY to $75M) and dividends steady/up in most (e.g., Steel Dynamics +6%). Acquisitions boosted assets in 6 filings (e.g., SEI goodwill +9.4% QoQ, Alternus +644%), signaling growth conviction amid sector rotation. Portfolio-level patterns flag real estate resilience via sales gains (Brixmor net income +83%) but debt rises; market implications point to tactical longs in cyclicals/metals, caution in consumer/discretionary.

28 high priority 28 total filings
· daily

US SEC Trading Suspension Halt Orders — April 27, 2026

In the USA Trading Suspensions stream, two Nasdaq-listed small caps show divergent compliance trajectories: Greenlane Holdings (GNLN) resolved its minimum bid price deficiency in under a month, averting a May 5, 2026 delisting hearing, while Gulf Resources (GURE) received a fresh notice for delayed 10-K filing, risking delisting proceedings. No direct period-over-period financial trends available, but Greenlane's rapid compliance regain (from March 25 notice to April 21 resolution) contrasts sharply with Gulf's ongoing filing delay for FY 2025 ended Dec 31, 2025. Board-affiliated warrant holders at Greenlane locked up 162,760 warrants until April 23, 2027, signaling conviction amid resolved risk. Gulf faces a 60-day compliance plan deadline (~June 22, 2026) with potential extension to October 12, 2026. Overarching theme: Heightened Nasdaq scrutiny on small-cap governance and reporting, with positive resolution in bid price issues but persistent late-filing risks. Market implications include potential relief rally for GNLN and downside pressure on GURE, highlighting portfolio-level vigilance on delisting catalysts in micro-caps.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 27, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, themes reveal a bifurcated landscape: robust M&A activity (e.g., Organon acquired for $11.75B EV, XOMA for $739M) and capital raises (e.g., Auddia $10.9M net, Velo3D $50M) signal strategic rescues amid distress, while restatements, late filings, and reverse splits (Driven Brands, Gulf Resources, Jaguar Health) underscore ongoing reporting and compliance woes. Period-over-period trends show mixed financial health, with Fulcrum Therapeutics' Q1 2026 net loss widening 7% YoY to $18.9M (R&D +5% YoY, G&A +16% YoY) contrasting positive guidance raises (Ligand 2026 revenue to $270-310M from $245-285M). Credit facility amendments dominate (10+ filings, e.g., SiteOne, Morgan Stanley Direct Lending $1.45B commitments), suggesting proactive liquidity management but potential covenant strains. No widespread bankruptcy filings, but 4/31 exhibit acute distress signals like delisting risks and financial restatements. Forward-looking catalysts cluster in H2 2026 (e.g., Fulcrum registration trial, multiple deal closes), with capital allocation favoring equity offerings (7 cases) over dividends/buybacks. Portfolio-level: positive sentiment in 11/31 (35%), negative in 4/31 (13%), implying selective turnaround opportunities amid neutral refinancing noise.

31 high priority 31 total filings
· daily

US Executive Officer Management Changes SEC — April 27, 2026

Across 32 SEC filings on US executive and director changes from April 27, 2026, the dominant theme is proactive leadership transitions, with 18 appointments/promotions (e.g., CEOs at agilon health, Crane Co, AIG) and 14 resignations/retirements (e.g., CFOs at Avient, NVIDIA, PACS), signaling board refreshment amid growth strategies. Positive sentiment prevails in 12 filings (38%), particularly high-materiality CEO successions in insurance (AIG), healthcare (agilon, PACS), and industrials (Crane, Booz Allen), while neutrals dominate routine changes; one mixed (Health Catalyst workforce cuts). Period trends highlight PACS Group's revenue surge to $5.29B (+29.3% YoY from 2 to 323 facilities), Booz Allen's $12B TTM revenue (ended Mar 31, 2025), contrasting no broad margin compression but RSU grants averaging 500K+ shares in Suncrete, LSB. Capital allocation favors equity incentives (e.g., Suncrete 528K RSUs vesting 2-3 yrs, NVIDIA $12.9M RSUs), with no dividend/buyback shifts noted. Portfolio implication: Bullish for stable large-caps with internal promotions; watch healthcare churn for execution risks. Upcoming catalysts include AIG Q1 earnings May 1 and Trupanion AGM June 10.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 27, 2026

Across 32 US SEC filings on boardroom changes from April 27, 2026 period, the dominant theme is proactive leadership transitions with 18 CEO/CFO/executive changes and 12 board appointments/resignations, emphasizing stability via internal promotions (8 cases) and experienced external hires. Positive sentiment prevails in 12/32 filings (38%), particularly high-materiality CEO successions at AIG (9/10), agilon health (10/10), and Crane Co (8/10), signaling management continuity amid sector growth; neutral in 18/32 with routine changes. Limited period-over-period financials show outliers like PACS Group revenue +29.3% YoY to $5.29B under outgoing CFO, contrasting Health Catalyst's 9% workforce cut. No broad margin compression or revenue trends emerge, but capital allocation via RSU grants (e.g., Suncrete 528K shares, NVIDIA $12.9M new hire) indicates alignment. Healthcare (6 filings) and financials (7 filings) lead activity, with smooth transitions reducing execution risk but watch for unfilled roles like Guardant CMO.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — April 27, 2026

The 12 filings reveal a surge in SPAC-driven M&A activity, with 8/12 (67%) involving SPACs at various stages: 3 business combinations announced (Miluna/CADV.AI at $300M pre-money, Aerkomm/Ejectt via 65M shares, AParadise/Enhanced), 3 extensions (Charlton Aria to July 2026, International Media 17th extension to June 2026), promissory notes (Andretti, Keen Vision), governance updates (Dune II), and IPO success (QuasarEdge full over-allotment adding $15M). Two major completed deals: BioMarin/Amicus $4.8B all-cash adding Fabry/Pompe assets, and Focus Universal real property acquisition; Amicus post-merger governance. Positive sentiment in 4/12 (33%), neutral 7/12, mixed 1/12; no explicit YoY/QoQ declines but SPAC extensions signal prolonged target searches vs. swift closings in non-SPACs. Forward-looking catalysts cluster in H2 2026 (Miluna close, extensions), with BioMarin guidance May 4, 2026. Implications: heightened M&A pipeline supports takeover premiums, but SPAC delays risk redemptions; pharma consolidation accelerates rare disease growth.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 27, 2026

Across 50 overnight SEC filings, dominant themes include a surge in proxy materials for 2026 annual meetings (e.g., RYTHM, Velo3D, SkyWater), signaling governance focus amid equity plan expansions, alongside high-materiality M&A (Organon acquisition at 103% premium, Cintas-UniFirst merger) and mixed Q1 earnings (Domino's rev +3.5% YoY but EPS -4.6%; Heartland rev -19.7% YoY). Period-over-period trends reveal revenue declines in 4/6 reporting companies (avg -28% YoY: Heartland -19.7%, Alternus -100%, Ladder other income flat), offset by margin improvements (Domino's ops income +9.6%, Heartland OR +490bps) and debt reductions (New ERA $50M prepaid, Heartland debt to $149.9M). Institutional 13Fs (9 filings) show heavy tech concentration (Apple, Amazon top holdings across managers). Positive catalysts dominate pharma/biotech (Organon deal, Adagio trials, Seaport IPO), while risks emerge in financial restatements (Driven Brands) and cyber incidents (Medtronic). Portfolio-level, capital returns strengthen (Domino's $1B buyback + $1.99 div), but loss-making trends persist in transport/energy. Actionable: Arbitrage M&A, monitor proxy votes for equity dilution.

22 high priority 28 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — April 26, 2026

The analyzed period features a single federal construction contract totaling $1,585,324,926 in obligations, entirely civilian with zero defense-related awards (0/1 split). Department of Homeland Security is the dominant agency, awarding the full $1.59B to BARNARD CONSTRUCTION COMPANY, INCORPORATED. This represents the highest-conviction bullish signal (strength 7/10, materiality 8/10) for infrastructure growth in DHS-aligned construction. The award underscores civilian agency infrastructure priorities amid sparse defense activity. A key risk watch item is the unknown competition signal, potentially exposing the award to protests or re-competition vulnerabilities.

1 total filings
· daily

DHS Homeland Security Contracts — April 26, 2026

DHS dominated obligations with a single $1,585,324,926 contract award to BARNARD CONSTRUCTION COMPANY, INCORPORATED, representing 100% of the period's activity in civilian homeland security contracts (0/1 defense-related). This massive award signals bullish momentum for construction in DHS priorities, with highest materiality (8/10) and strength (7/10). No defense split applies, underscoring pure civilian exposure via DHS. The dominant theme is large-scale DHS construction procurement. Key watch item: unknown competition signal and pricing risk could impact durability.

1 total filings
· daily

New Federal Contractors — April 26, 2026

This one-day snapshot captures $1,907,292,467 in new federal obligations across 4 civilian contracts (0 defense-related), dominated by a massive $1.585B Department of Homeland Security award to Barnard Construction Company, Incorporated. GSA features in two smaller IT-related awards to CGI Federal Inc. ($147M) and Lockheed Martin Corporation ($6.65M), while HHS granted $168M to Potomac Electric Power Co. Highest-conviction bullish signal is Barnard's $1.59B DHS construction contract (materiality 8/10), signaling strong civilian infrastructure demand. Key watch item: multiple contracts (CGI, Lockheed) show $0 outlays to date, risking delayed revenue recognition.

4 total filings
· daily

Significant Contract Modifications ($10M+) — April 26, 2026

This week's $1,907,292,467 in significant contract modifications (4 total) are entirely civilian-agency focused (0/4 defense-related), with DHS dominating via a massive $1.585B award to Barnard Construction Company, Incorporated. Bullish signals center on Barnard's high-materiality DHS win (8/10) and CGI Federal Inc.'s $147M GSA IT delivery order (base + options $289M), signaling robust demand for construction and federal IT services. GSA also issued smaller neutral awards to Potomac Electric Power Co ($168M HHS grant) and Lockheed Martin Corporation ($6.7M F16 simulators). Highest-conviction bullish signal is Barnard's $1.59B scale amid unknown revenue impact; key watch item is zero outlays to date on CGI and Lockheed GSA contracts, risking delayed revenue recognition.

4 total filings